- Home
- TCRX vs GDL Comparison
TCRX vs GDL Comparison
Compare TCRX & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- GDL
- Stock Information
- Founded
- TCRX 2018
- GDL 2006
- Country
- TCRX United States
- GDL United States
- Employees
- TCRX N/A
- GDL N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- GDL Investment Managers
- Sector
- TCRX Health Care
- GDL Finance
- Exchange
- TCRX Nasdaq
- GDL Nasdaq
- Market Cap
- TCRX 91.7M
- GDL 93.3M
- IPO Year
- TCRX 2021
- GDL N/A
- Fundamental
- Price
- TCRX $1.79
- GDL $8.39
- Analyst Decision
- TCRX Strong Buy
- GDL
- Analyst Count
- TCRX 6
- GDL 0
- Target Price
- TCRX $9.50
- GDL N/A
- AVG Volume (30 Days)
- TCRX 255.2K
- GDL 11.2K
- Earning Date
- TCRX 08-12-2025
- GDL 01-01-0001
- Dividend Yield
- TCRX N/A
- GDL 6.02%
- EPS Growth
- TCRX N/A
- GDL N/A
- EPS
- TCRX N/A
- GDL N/A
- Revenue
- TCRX $6,961,000.00
- GDL N/A
- Revenue This Year
- TCRX $159.20
- GDL N/A
- Revenue Next Year
- TCRX N/A
- GDL N/A
- P/E Ratio
- TCRX N/A
- GDL N/A
- Revenue Growth
- TCRX N/A
- GDL N/A
- 52 Week Low
- TCRX $1.02
- GDL $7.65
- 52 Week High
- TCRX $6.23
- GDL $8.13
- Technical
- Relative Strength Index (RSI)
- TCRX 54.34
- GDL 55.39
- Support Level
- TCRX $1.60
- GDL $8.24
- Resistance Level
- TCRX $1.86
- GDL $8.40
- Average True Range (ATR)
- TCRX 0.10
- GDL 0.07
- MACD
- TCRX 0.00
- GDL 0.00
- Stochastic Oscillator
- TCRX 70.37
- GDL 95.79
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.